Deerfield Management Confirms Successful Sale of Melinta Therapeutics to CorMedix, Inc.

Deerfield Management's Transformative Sale of Melinta Therapeutics

In an impressive display of strategic investment and operational enhancement, Deerfield Management Company recently announced the successful completion of the sale of Melinta Therapeutics to CorMedix, Inc. This deal, finalized on September 5, 2025, underscores Deerfield's ability to merge financial prowess with operational skills, creating significant value within the healthcare sector.

Deerfield had initially acquired Melinta in 2020, taking full private ownership as part of a financial restructuring process. During its stewardship, Deerfield aimed to leverage its extensive capabilities—from operational management and business development to data analytics and market insights—to foster sustainable growth for Melinta's diverse product portfolio. Jonathan Leff, a partner at Deerfield and a member of Melinta's board, noted that when they took on Melinta, they identified considerable potential within a niche market—hospital antibiotics—with a dedicated workforce but lacking a cohesive leadership structure and strategic roadmap.

Under Deerfield’s guidance, Melinta rapidly evolved. The recruitment of seasoned professionals, notably CEO Christine Ann Miller, played a pivotal role in this transformation. The company not only doubled its revenue but also achieved positive cash flow and established long-term profitability. Today, Melinta boasts six marketed products in the infectious disease sector, including REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), and TOPROL-XL® (metoprolol succinate), among others.

Christine Ann Miller praised the partnership with Deerfield, emphasizing its critical contribution to Melinta's development into a leader in hospital and acute care. “Their strategic guidance and profound understanding of complex care environments empowered us to establish a commercial framework that addresses the unique demands of hospitals,” she remarked. This collaboration ensured that vital therapies reached patients during their most vulnerable moments, amplifying their potential impact on acute care.

Jim Flynn, Managing Partner at Deerfield, expressed his pride in the positive transformation Melinta underwent, declaring it a testament to Deerfield's unique operational, product development, and deal-making capabilities in the healthcare landscape. The acquisition required innovative financing strategies and significant engagement to help Melinta emerge as a robust player in the infectious disease market.

Overall, the successful sale of Melinta Therapeutics not only reflects Deerfield Management's adeptness at realizing growth and value but also marks a significant milestone in the ongoing evolution of healthcare investment strategies. With a commitment to advancing healthcare through investment and intelligence, Deerfield continues to promote innovation that resonates across the industry.

To learn more about Deerfield Management and its impact on the healthcare ecosystem, visit their official website at www.deerfield.com.